| 2.16 0 (0%) | 09-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.7 | 1-year : | 3.16 |
| Resists | First : | 2.31 | Second : | 2.7 |
| Pivot price | 2.18 |
|||
| Supports | First : | 2.12 | Second : | 2 |
| MAs | MA(5) : | 2.13 |
MA(20) : | 2.14 |
| MA(100) : | 2.07 |
MA(250) : | 1.91 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 36.7 |
D(3) : | 36.2 |
| RSI | RSI(14): 52.6 | |||
| 52-week | High : | 2.95 | Low : | 0.99 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TXMD ] has closed above bottom band by 39.0%. Bollinger Bands are 15% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.18 - 2.19 | 2.19 - 2.2 |
| Low: | 2.12 - 2.14 | 2.14 - 2.15 |
| Close: | 2.13 - 2.16 | 2.16 - 2.18 |
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Tue, 11 Aug 2026
TherapeuticsMD, Inc. (TXMD) Total Assets 2025: $37.7M, down 3.0% - Stock Titan
Tue, 11 Aug 2026
TherapeuticsMD (TXMD) posts Q2 2026 update and weighs strategic alternatives - Stock Titan
Wed, 05 Aug 2026
Baselake group (TXMD) discloses 6.8% beneficial stake in TherapeuticsMD common stock - Stock Titan
Thu, 30 Jul 2026
TherapeuticsMD Inc. (TXMD) Slips Further: Key Support Levels Under Pressure - Smart Beta Flow - Vinanet
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 12 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 9 (%) |
| Held by Institutions | 31.7 (%) |
| Shares Short | 28 (K) |
| Shares Short P.Month | 43 (K) |
| EPS | -0.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.32 |
| Profit Margin | -6.7 % |
| Operating Margin | -32.3 % |
| Return on Assets (ttm) | -2.9 % |
| Return on Equity (ttm) | -1.1 % |
| Qtrly Rev. Growth | -8.7 % |
| Gross Profit (p.s.) | 0.28 |
| Sales Per Share | 0.28 |
| EBITDA (p.s.) | -0.12 |
| Qtrly Earnings Growth | -80.6 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -72.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.92 |
| Price to Sales | 7.64 |
| Price to Cash Flow | 8.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|